Stockscreener 앱 받기
4.67
9.85%
-0.51
시간 외 거래:
4.67
전일 마감가:
$5.18
열려 있는:
$5.12
하루 거래량:
1.12M
Relative Volume:
1.17
시가총액:
$280.96M
수익:
-
순이익/손실:
$-44.80M
주가수익비율:
-6.2267
EPS:
-0.75
순현금흐름:
$-30.67M
1주 성능:
-12.05%
1개월 성능:
-4.11%
6개월 성능:
+16.75%
1년 성능:
-10.54%
1일 변동 폭
$4.65
$5.205
1주일 범위
$4.65
$5.31
52주 변동 폭
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
4.67 | 311.64M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 재개 | H.C. Wainwright | Buy |
| 2022-04-27 | 재개 | H.C. Wainwright | Buy |
| 2021-02-08 | 개시 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-10-30 | 개시 | Jefferies | Buy |
| 2020-10-16 | 개시 | BTIG Research | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-12 | 개시 | Oppenheimer | Outperform |
| 2018-12-04 | 개시 | Citigroup | Buy |
| 2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Janney | Buy |
| 2018-01-26 | 개시 | Seaport Global Securities | Buy |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2016-07-01 | 개시 | Stifel | Buy |
| 2015-07-01 | 개시 | Canaccord Genuity | Buy |
| 2015-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2015-03-20 | 재확인 | H.C. Wainwright | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
| 2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Aldeyra Therapeutics Chief Development Officer Stephen Machatha to Resign - marketscreener.com
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Aldeyra Therapeutics chief development officer to step down by March 2026 - Investing.com Nigeria
Aldeyra Therapeutics Announces Chief Development Officer Resignation - TipRanks
Aldeyra Therapeutics Announces Resignation of Chief Development Officer - TradingView — Track All Markets
Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) Institutional Shareholders Had a Great Week as One-year Returns Increased After a 24% Gain Last Week - 富途牛牛
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Can SAL Steel Limited Maintain Growth Without Diluting ShareholdersLong-Term Investment Plans & Small Investment Capital Gains - earlytimes.in
Targets Report: Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Earnings Recap Report & Weekly Watchlist of Top Performers - Улправда
Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Trade Analysis Report & Daily Market Momentum Tracking - ulpravda.ru
Can Aldeyra Therapeutics Inc. stock rebound after recent weaknessPrice Action & Community Verified Trade Signals - DonanımHaber
What dividend safety score for Aldeyra Therapeutics Inc. stockMarket Trend Summary & Reliable Trade Execution Plans - DonanımHaber
What Wall Street predicts for Aldeyra Therapeutics Inc. stock priceWeekly Stock Summary & Real-Time Market Sentiment Reports - Улправда
Why is Aldeyra Therapeutics stock surging after FDA delayed its dry eye drug decision? - MSN
Will Aldeyra Therapeutics Inc. stock benefit from infrastructure spendingSwing Trade & Fast Gaining Stock Strategy Reports - Улправда
ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being InvestigatedContact the Firm if You Lost Money - 28/22 News
Aldeyra Therapeutics Sees Unusually Large Options Volume (NASDAQ:ALDX) - Defense World
Aldeyra drops as FDA delays review of marketing application for lead drug - MSN
Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX) - MarketBeat
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside - TipRanks
Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? - Asianet Newsable
Aldeyra Therapeutics (NASDAQ: ALDX) updates on FDA review of reproxalap - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
ALDX: FDA extends reproxalap NDA review by 90 days after requiring field trial CSR submission - TradingView — Track All Markets
FDA Extends Review Timeline For Aldeyra's Dry Eye Disease Drug - Sahm
Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxala - GuruFocus
Why Is Aldeyra Therapeutics Stock Falling Tuesday?Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Transcript : Aldeyra Therapeutics, Inc.Special Call - marketscreener.com
Aldeyra stock drops on FDA delay for lead drug (ALDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Aldeyra Therapeutics Faces FDA PDUFA Date Extension - TipRanks
Aldeyra Says FDA Extends Action Date for Potential Dry Eye Disease Treatment; Shares Down Pre-Bell - marketscreener.com
Aldeyra Therapeutics Announces PDUFA Extension for Reproxalap NDA - TradingView — Track All Markets
Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket - Benzinga
Aldeyra (ALDX) Receives Extended FDA Action Date for Reproxalap NDA - GuruFocus
Aldeyra (Nasdaq: ALDX) PDUFA review of reproxalap dry eye NDA extended to Mar. 2026 - Stock Titan
Aldeyra Therapeutics announces PDUFA extension of the new drug application of Reproxalap for the treatment of dry eye disease - marketscreener.com
683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX - MarketBeat
Adversity is less terrifying than hope: Aldeyra Therapeutics Inc (ALDX) - setenews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc.ALDX - 28/22 News
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Aldeyra Therapeutics, Inc. $ALDX Shares Sold by Kennedy Capital Management LLC - MarketBeat
Winners Losers: Will Aldeyra Therapeutics Inc stock maintain momentum in 2025 - BỘ NỘI VỤ
It makes sense and dollars to buy Aldeyra Therapeutics Inc (ALDX) stock - setenews.com
Aldeyra Therapeutics Inc (137.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Aldeyra Therapeutics Inc. stock oversold or undervaluedCEO Change & Smart Allocation Stock Reports - Newser
FDA’s docket holds 16 more PDUFA dates by year-end - biocentury.com
Can Aldeyra Therapeutics Inc. stock deliver surprise earnings beatChart Signals & Long-Term Capital Growth Strategies - moha.gov.vn
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.57%
자본화:
|
볼륨(24시간):